Pharmacokinetics of Levodopa/Carbidopa Infusion With and Without Oral Catechol-O-methyl Transferase (COMT) Inhibitors

• Status: Completed
• Trial end date: 2009-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether oral intake of COMT inhibitors affects the smooth plasma levodopa levels achieved by intestinal levodopa/carbidopa infusion in advanced Parkinson's disease patients. The hypothesis is that COMT inhibitors make plasma concentrations of levodopa more fluctuating.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Uppsala University
• Collaborators: Swedish Parkinson's Disease Foundation; Swedish Society for Medical Research
• Treatments: Carbidopa; Carbidopa, levodopa drug combination; Catechol O-Methyltransferase Inhibitors; Entacapone; Levodopa; Tolcapone

Criteria

Inclusion Criteria:

• Parkinson's disease

• Duodopa treatment ongoing

• Hoehn & Yahr stage 3-5 at worst

Exclusion Criteria:

• Ongoing treatment with COMT inhibitors

• Dementia

• Psychosis

• Treatment with typical neuroleptics

• Contraindications for entacapone or tolcapone